Saurashtra News

Acute Ocular Pain Market: Industry Analysis, Epidemiology, Pipeline Therapies, Treatment and Companies by DelveInsight

 Breaking News
  • No posts were found

Acute Ocular Pain Market: Industry Analysis, Epidemiology, Pipeline Therapies, Treatment and Companies by DelveInsight

November 08
16:16 2021
Acute Ocular Pain Market: Industry Analysis, Epidemiology, Pipeline Therapies, Treatment and Companies by DelveInsight
Acute Ocular Pain Market

DelveInsight’s “Acute Ocular Pain Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Acute Ocular Pain , historical and forecasted epidemiology as well as the Acute Ocular Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Eye pain is a myriad of symptoms ranging from a sharp pain in the eye to mild discomfort or itching in the eyes. As the spectrum of symptom presentation varies with eye pain, the cause of these pains may vary from straightforward refractive errors to potentially sight-threatening disorders like glaucoma and uveitis. A feeling of discomfort or pain in the eye can be caused by a problem in the eye itself.


Some key facts of Acute Ocular Pain Market Report are:

  • Acute Ocular Pain Market Size in the 7MM was estimated to be USD 276.02 million in 2020, and it is estimated to grow at a Compound Annual Growth Rate (CAGR) of 8.93% for the study period (2018–2030).
  • In the year 2020, the total cases of Acute Ocular Pain (AOP) were estimated to be 15,029,051 cases in the 7MM, which might increase in 2030 at a CAGR of 0.65%.
  • According to DelveInsight estimates, in 2020, it was estimated that there were 461,948, 14,243, 98,281, 710,949, 1,268,905 and 4,050,494 cases of Cataract Surgeries, Uveitis, Glaucoma Surgeries, Corneal Aberration Surgeries, Dry eye disease, and Conjunctivitis respectively that experienced acute ocular pain, in the United States.
  • Among EU5 countries, Spain has the lowest number of cases of Acute Ocular Pain (AOP), which were estimated to be 1,106,840 cases in 2020.
  • Dextenza, Inveltys, and Lotemax SM—already approved in the US market—are expected to enter the European and Japan market in 2023, 2024, and 2024, respectively.


Request for Free Sample Report:


Scope of the Acute Ocular Pain Market Report

  • The report covers the descriptive overview of AOP, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the AOP epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for AOP is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the AOP market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM AOP market.


Request for Free Sample Report:


Some of Acute Ocular Pain Companies are:

  • Ocular Therapeutix
  • Kala Pharmaceuticals
  • Sun Pharmaceutical
  • Bausch & Lomb
  • Formosa Pharmaceuticals
  • Aldeyra Therapeutics
  • Sylentis
  • And Many Others


Acute Ocular Pain therapies are:

  • Dextenza (dexamethasone ophthalmic insert)
  • Inveltys (loteprednol etabonate ophthalmic suspension/KPI-121)
  • BromSite (bromfenac ophthalmic solution)
  • Lotemax SM (loteprednol etabonate ophthalmic gel)
  • Prolensa (bromfenac ophthalmic solution) 0.07%
  • APP13007
  • Reproxalap
  • Tivanisiran (SYL1001)
  • And Many Others


Request for Free Sample Report:


Table of Contents:

1. Key Insights

2. Executive Summary of Acute Ocular Pain

3. Competitive Intelligence Analysis for Acute Ocular Pain

4. Acute Ocular Pain : Market Overview at a Glance

5. Acute Ocular Pain : Disease Background and Overview

6. Patient Journey

7. Acute Ocular Pain Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Acute Ocular Pain Treatment

11. Marketed Products

12. Emerging Therapies

13. Acute Ocular Pain : Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Acute Ocular Pain

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer


About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States

Related Articles